Holen Sie sich die Stockscreener-App
1.56
0.64%
-0.01
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Gain Therapeutics' SWOT analysis: protein misfolding stock faces pivotal phase - Investing.com India
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Stock market news: Wintest surges 26.25%, Smaregi drops 16.74%, D. Western Therapeutics gains 25.96% in volatile midday trading - Business Upturn
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Short Interest Update - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short Interest - MarketBeat
NCATS Helped Develop a Gene Therapy for a Rare Brain Disorder - NCBI
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast - Benzinga
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Gain Therapeutics To Present At Biotech Showcase 2025 - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Design Therapeutics Gains 11%, Insider Trades Reap Benefit - Simply Wall St
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - Yahoo Finance
Roth Mkm Begins Coverage on Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics (NASDAQ:GANX) Upgraded at Roth Capital - Defense World
GANX shares initiated with buy rating on preclinical trials By Investing.com - Investing.com Canada
Roth MKM Initiates Coverage of Gain Therapeutics (GANX) with Buy Recommendation - MSN
GANX shares initiated with buy rating on preclinical trials - Investing.com
Gain Therapeutics' SWOT analysis: protein misfolding drug developer's stock outlook - Investing.com Canada
TMO Stock to Gain From the New Additions to CTS Portfolio of Products - Yahoo Finance
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results - Benzinga
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup - Marketscreener.com
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Gene Therapy Explosion Forces Employer Coverage to Get Creative - Bloomberg Law
S&P 500, Dow close at record highs on tech gains - Yahoo Finance
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - Yahoo Finance
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
HC Wainwright Lifts Earnings Estimates for Gain Therapeutics - Defense World
HC Wainwright Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Stock market today: Poseida Therapeutics +224.30%, Primega Group Holdings +98.77% among the top gainers in early trading - Business Upturn
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology - Yahoo Finance
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs - Yahoo Finance
Gain Therapeutics shares hold Buy rating; H.C. Wainwright optimistic on GT-02287 clinical data - Investing.com India
FY2024 Earnings Forecast for GANX Issued By Chardan Capital - Defense World
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Nasdaq
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn
Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Tapestry (NYSE:TPR) Price Target Raised to $66.00 - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients - STAT
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Gain Therapeutics Inc (GANX) Quarterly 10-Q Report - Quartz
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - The Manila Times
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):